Combination vaccine and drug for recurrent astrocytoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new vaccine plus an oral drug for people whose astrocytoma (a type of brain tumor) has come back after standard treatments. The goal is to see if the combination is safe and can help the immune system fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a recurrent astrocytoma that has returned 1 to 3 times after treatment with radiation and chemotherapy.
- Your tumor must have a specific mutation called IDH1 R132H.
- You are able to have surgery to remove part or all of the tumor, and that surgery can be delayed for up to 6 weeks.
- You are in generally good health, able to care for yourself (Karnofsky score of 70 or above), and have adequate blood, kidney, and liver function.
- You are not taking high-dose steroids (over 2 mg/day of dexamethasone) and have not previously been treated with an IDH inhibitor or IDH1 vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
This trial tests a combination of two oral medications (vorasidenib and lomustine) for people whose brain tumor (glioma) has come back and has an IDH1 or IDH2 mutation. The goal is to see if this combination is safe and effective in halting or slowing tumor growth.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
This trial studies an oral drug called vorasidenib for children and teens with a slow-growing brain tumor (Grade 2 astrocytoma or oligodendroglioma) that has an IDH1 or IDH2 mutation. The drug is taken daily and may help keep the tumor from growing, avoiding the need for immediate chemotherapy or radiation.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (a drug that blocks blood vessel growth to tumors)—for people with astrocytoma that has come back. The goal is to see if this combination can slow or stop the tumor's growth.
Hear when a new Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.